New Oral Eczema Drug Advances in Asia

Adults with moderate-to-severe atopic dermatitis in the covered regions may gain a new pill option if regulators approve it.

Updated on Nov. 2, 2026 in Arthritis

Bold vector editorial illustration of a teal oval tablet beside an outlined landmass shape, joined by a thin coral line on a cream field.
Lynk Pharmaceuticals expanded its partnership with Simcere Pharmaceutical Group to commercialize oral zemprocitinib for atopic dermatitis across Chinese Mainland, Macau, Hong Kong and Taiwan. AI Illustration. Upload story photo >

Lynk Pharmaceuticals has expanded its commercialization partnership with Simcere Pharmaceutical Group for zemprocitinib, an oral JAK1 inhibitor. Simcere will gain exclusive rights in Chinese Mainland, Macau, Hong Kong and Taiwan for dermatology indications, including moderate-to-severe atopic dermatitis in adults.

Why it matters

For people with inflammatory skin and joint conditions in these regions, the expansion aims to speed development and access to a new oral option. The Phase III results and the regulatory review that is now underway will determine whether the drug becomes available.

The atopic dermatitis indication has completed a pivotal Phase III study in adults with moderate-to-severe disease, and a rheumatoid arthritis Phase III study has also been completed. Specific trial sizes and outcome measures were not included in the source.

The players

Lynk Pharmaceuticals

A Hangzhou-based drugmaker developing zemprocitinib for immune-mediated conditions including rheumatoid arthritis, ankylosing spondylitis and atopic dermatitis.

Simcere Pharmaceutical Group

A Chinese pharmaceutical company that will hold exclusive commercialization rights for zemprocitinib in dermatology across Mainland China, Macau, Hong Kong and Taiwan.

China's Center for Drug Evaluation

China's national regulator that reviews new drug applications, including the zemprocitinib application accepted in April 2026.

The details

Zemprocitinib is a highly selective, oral second-generation JAK1 inhibitor, meaning it targets a specific enzyme involved in signaling pathways that drive inflammation. Because it is taken by mouth, it offers an alternative to injectable biologic therapies for suitable patients. Under the expanded collaboration, Simcere takes on commercialization across Chinese Mainland, Macau, Hong Kong and Taiwan, building on a 2022 partnership that initially covered rheumatoid arthritis and ankylosing spondylitis.

Timeline

  1. March 2022: Lynk and Simcere signed the initial commercialization collaboration for rheumatoid arthritis and ankylosing spondylitis.

  2. April 2026: China's Center for Drug Evaluation accepted the New Drug Application for review.

  3. November 2, 2026: The expanded dermatology collaboration was announced.

Health Landscape

Zemprocitinib belongs to the JAK inhibitor class of oral immunomodulatory drugs, which has offered an alternative to injectable biologics for autoimmune conditions. This second-generation, more selective agent is now being developed for dermatology as well as joint disease.

If you live in the covered regions and have been living with rheumatoid arthritis, ankylosing spondylitis or atopic dermatitis, an oral option may become available if approvals follow. It is worth discussing with your doctor whether any emerging treatment fits your condition, since no approval or dosing guidance exists yet.

The takeaway

Expanded partnerships can speed a drug toward patients, but approval is still pending and trial details are not yet public. If you have one of these conditions, ask your physician whether newer oral therapies are appropriate to discuss as they become available.

What happens next

Phase III results for ankylosing spondylitis and China's review of the atopic dermatitis application are expected to be the next milestones, though no dates were given in the source.

Further reading

Explore more on Arthritis to see how new oral and biologic treatments are reshaping care for joint and immune conditions.